Despite the wealth of pre-clinical support for a role for reactive oxygen and nitrogen species (ROS/RNS) in the aetiology of diabetic complications, enthusiasm for antioxidant therapeutic approaches has been dampened by less favourable outcomes in large clinical trials. This has necessitated a re-evaluation of pre-clinical evidence and a more rational approach to antioxidant therapy. The present review considers current evidence, from both pre-clinical and clinical studies, to address the benefits of antioxidant therapy. The main focus of the present review is on the effects of direct targeting of ROS-producing enzymes, the bolstering of antioxidant defences and mechanisms to improve nitric oxide availability. Current evidence suggests that a more nuanced approach to antioxidant therapy is more likely to yield positive reductions in end-organ injury, with considerations required for the types of ROS/RNS involved, the timing and dosage of antioxidant therapy, and the selective targeting of cell populations. This is likely to influence future strategies to lessen the burden of diabetic complications such as diabetes-associated atherosclerosis, diabetic nephropathy and diabetic retinopathy.
Are reactive oxygen species still the basis for diabetic complications?
Elyse Di Marco, Jay C. Jha, Arpeeta Sharma, Jennifer L. Wilkinson-Berka, Karin A. Jandeleit-Dahm, Judy B. de Haan; Are reactive oxygen species still the basis for diabetic complications?. Clin Sci (Lond) 1 July 2015; 129 (2): 199–216. doi: https://doi.org/10.1042/CS20150093
Download citation file: